<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LABETALOL HYDROCHLORIDE- labetalol hydrochlorideÂ injection, solutionÂ </strong><br>Hospira, Inc.<br></p></div>
<h1>Labetalol Hydrochloride</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d79c8fb9-4caf-4138-8fdb-bb4e6c66ef4e"></a><a name="section-1"></a><p></p>
<p class="First">Injection, USP</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <a name="id346069641"></a><img alt="Novaplus logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f6e529bf-fe4d-4091-a3c2-774245b5f0a1&amp;name=novaplus-logo-01.jpg"><br>Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="daba97cd-e8eb-4b48-b404-7d9d874e46ee"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Labetalol hydrochloride is an adrenergic receptor blocking agent that has both selective alpha<span class="Sub">1</span>- and nonselective beta-adrenergic receptor blocking actions in a single substance.</p>
<p>Labetalol HCl is a racemate, chemically designated as 5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl) amino] ethyl]-salicylamide monohydrochloride, and has the following structural formula:</p>
<div class="Figure">
<a name="id267"></a><img alt="structural formula labetalol hcl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f6e529bf-fe4d-4091-a3c2-774245b5f0a1&amp;name=labetalol-hydrochloride-injection-usp4-figure-1-xPI040-KB-01.jpg">
</div>
<p>Labetalol hydrochloride has the molecular formula C<span class="Sub">19</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">3</span> â€¢ HCl and a molecular weight of 364.87. It has two asymmetric centers and therefore exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R,Râ€™ stereoisomer, makes up 25% of racemic labetalol.</p>
<p>Labetalol hydrochloride is a white or off-white crystalline powder, soluble in water.</p>
<p>Labetalol hydrochloride injection is a clear, colorless to light yellow aqueous sterile isotonic solution for intravenous injection. It has a pH range of 3.0 to 4.5. Each mL contains 5 mg labetalol hydrochloride, USP, 45 mg anhydrous dextrose, 0.1 mg edetate disodium; 0.8 mg methylparaben and 0.1 mg propylparaben as preservatives; citric acid monohydrate and sodium hydroxide, as necessary, to bring the solution into the pH range.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ae596418-c6ac-4ac3-858a-27df7c58a465"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Labetalol combines both selective, competitive alpha<span class="Sub">1</span>-adrenergic blocking and nonselective, competitive beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta-blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous administration, respectively. Beta<span class="Sub">2</span>-agonist activity has been demonstrated in animals with minimal beta<span class="Sub">1</span>-agonist (ISA) activity detected. In animals, at doses greater than those required for alpha- or beta-adrenergic blockade, a membrane-stabilizing effect has been demonstrated.</p>
<p><span class="Emphasis"><span class="Bold">Pharmacodynamics</span></span></p>
<p>The capacity of labetalol to block alpha-receptors in man has been demonstrated by attenuation of the presser effect of phenylephrine and by a significant reduction of the presser response caused by immersing the hand in ice-<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> water (â€œcold-presser testâ€?). Labetalolâ€™s beta<span class="Sub">1</span>-receptor blockade in man was demonstrated by a small decrease in the resting heart rate, attenuation of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> produced by isoproterenol or exercise, and by attenuation of the <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> to the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> produced by amyl nitrite. Beta<span class="Sub">2</span>-receptor blockade was demonstrated by inhibition of the isoproterenol-induced <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in diastolic blood pressure. Both the alpha- and beta-blocking actions of orally administered labetalol contribute to a decrease in blood pressure in hypertensive patients. Labetalol consistently, in dose-related fashion, blunted increases in exercise-induced blood pressure and heart rate, and in their double product. The pulmonary circulation during exercise was not affected by labetalol dosing.</p>
<p>Single oral doses of labetalol administered in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> had no significant effect on sinus rate, intraventricular conduction, or QRS duration. The atrioventricular (AV) conduction time was modestly prolonged in 2 of 7 patients. In another study, intravenous labetalol slightly prolonged AV nodal conduction time and atrial effective refractory period with only small changes in heart rate. The effects on AV nodal refractoriness were inconsistent.</p>
<p>Labetalol produces dose-related <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> in blood pressure without <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> and without significant reduction in heart rate, presumably through a mixture of its alpha-blocking and beta-blocking effects. Hemodynamic effects are variable with small nonsignificant changes in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> seen in some studies but not others, and small decreases in total peripheral resistance. Elevated plasma renins are reduced.</p>
<p>Doses of labetalol that controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> did not affect renal function in mild to severe hypertensive patients with normal renal function.</p>
<p>Due to the alpha<span class="Sub">1</span>-receptor blocking activity of labetalol, blood pressure is lowered more in the standing than in the supine position, and symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> can occur. During dosing with intravenous labetalol, the contribution of the postural component should be considered when positioning patients for treatment, and patients should not be allowed to move to an erect position unmonitored until their ability to do so is established.</p>
<p>In a clinical pharmacologic study in severe hypertensives, an initial 0.25 mg/kg injection of labetalol, administered to patients in the supine position, decreased blood pressure by an average of 11/7 mmHg. Additional injections of 0.5 mg/kg at 15 minute intervals up to a total cumulative dose of 1.75 mg/kg of labetalol caused further dose-related decreases in blood pressure. Some patients required cumulative doses of up to 3.25 mg/kg. The maximal effect of each dose level occurred within 5 minutes. Following discontinuation of intravenous treatment with labetalol, the blood pressure rose gradually and progressively approaching pretreatment baseline values within an average of 16 to 18 hours in the majority of patients.</p>
<p>Similar results were obtained in the treatment of patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> requiring urgent blood pressure reduction with an initial dose of 20 mg (which corresponds to 0.25 mg/kg for an 80 kg patient) followed by additional doses of either 40 or 80 mg at 10 minute intervals to achieve the desired effect or up to a cumulative dose of 300 mg.</p>
<p>Labetalol administered as a continuous intravenous infusion, with a mean dose of 136 mg (27Â to 300 mg) over a period of 2 to 3 hours (mean of 2 hours and 39 minutes) lowered the blood pressure by an average of 60/35 mmHg.</p>
<p>Exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Abrupt withdrawal of these agents in patients without <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> has resulted in transient symptoms, including <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta-receptors.</p>
<p>Although beta-adrenergic receptor blockade is useful in the treatment of angina and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, there are also situations in which sympathetic stimulation is vital. For example, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta-adrenergic blockade may worsen <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> by preventing the necessary facilitating effects of sympathetic activity on conduction. Beta<span class="Sub">2</span>-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and may also interfere with exogenous bronchodilators in such patients.</p>
<p><span class="Emphasis"><span class="Bold">Pharmacokinetics and Metabolism</span></span></p>
<p>Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg. The plasma half-life of labetalol following oral administration is about 6 to 8 hours. In patients with decreased hepatic or renal function, the elimination half-life of labetalol is not altered; however, the relative bioavailability in hepatically impaired patients is increased due to decreased â€œfirst-passâ€? metabolism.</p>
<p>The metabolism of labetalol is mainly through conjugation to glucuronide metabolites. These metabolites are present in plasma and are excreted in the urine and, via the bile, into the feces. Approximately 55% to 60% of a dose appears in the urine as conjugates or unchanged labetalol within the first 24 hours of dosing.</p>
<p>Labetalol has been shown to cross the placental barrier in humans. Only negligible amounts of the drug crossed the blood-brain barrier in animal studies. Labetalol is approximately 50% protein bound. Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol from the general circulation (&lt;1%).</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ba420de0-d6e9-412c-8b1c-48b38a56b8f0"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Labetalol HCl injection is indicated for control of blood pressure in severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="f12bbe45-a89d-4d0c-86f7-676a4101bca2"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Labetalol HCl injection is contraindicated in bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, greater than first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, other conditions associated with severe and prolonged <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the product (see <span class="Bold"><a href="#f4aaf679-d475-409b-a84a-225d94b0d447">WARNINGS</a></span>).</p>
<p>Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="f4aaf679-d475-409b-a84a-225d94b0d447"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Emphasis"><span class="Bold">Hepatic Injury </span></span></p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular injury</span>, confirmed by rechallenge in at least one case, occurs rarely with labetalol therapy. The hepatic injury is usually reversible, but <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported. Injury has occurred after both short- and long-term treatment and may be slowly progressive despite minimal symptomatology. Similar hepatic events have been reported with a related compound, dilevalol HCl, including two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Dilevalol HCl is one of the four isomers of labetalol. Thus, for patients taking labetalol, periodic determination of suitable hepatic laboratory tests would be appropriate. Laboratory testing should also be done at the very first symptom or sign of liver dysfunction (e.g., <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, dark urine, persistent <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or unexplained â€œflu-likeâ€? symptoms). If the patient has <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, labetalol should be stopped and not restarted.</p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></span></span></p>
<p>Sympathetic stimulation is a vital component supporting circulatory function in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Beta-blockade carries a potential hazard of further depressing myocardial contractility and precipitating more severe failure. Although beta-blockers should be avoided in overt <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, if necessary, labetalol can be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, who are well compensated. <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> has been observed in patients receiving labetalol. Labetalol does not abolish the inotropic action of digitalis on heart muscle.</p>
<p><span class="Emphasis"><span class="Bold">In Patients without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></span></span></p>
<p>In patients with latent <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac insufficiency</span>, continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can lead, in some cases, to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of impending <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, patients should be fully digitalized and/or be given a diuretic, and the response observed closely. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> continues, despite adequate digitalization and diuretic, labetalol therapy should be withdrawn (gradually if possible).</p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span> has not been reported upon labetalol discontinuation. However, following abrupt cessation of therapy with some beta-blocking agents in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, exacerbations of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported. Therefore, such patients should be cautioned against interruption of therapy without the physicianâ€™s advice. Even in the absence of overt <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, when discontinuation of labetalol is planned, the patient should be carefully observed and should be advised to limit physical activity. If angina markedly worsens or acute coronary insufficiency develops, labetalol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> should be taken.</p>
<p><span class="Emphasis"><span class="Bold">Nonallergic <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>)</span></span></p>
<p>Since labetalol injection at the usual intravenous therapeutic doses has not been studied in patients with nonallergic bronchospastic disease, it should not be used in such patients.</p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span> </span></span></p>
<p>Intravenous labetalol has been shown to be effective in lowering the blood pressure and relieving symptoms in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>; higher than usual doses may be required. However, paradoxical hypertensive responses have been reported in a few patients with this tumor; therefore, use caution when administering labetalol to patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.</p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> </span></span></p>
<p>Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This is especially important with labile diabetics. Beta-blockade also reduces the release of insulin in response to <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; it may therefore be necessary to adjust the dose of antidiabetic drugs.</p>
<p><span class="Emphasis"><span class="Bold">Major Surgery </span></span></p>
<p>Do not routinely withdraw chronic beta blocker therapy prior to surgery. The effect of labetalolâ€™s alpha adrenergic activity has not been evaluated in this setting. </p>
<p>Several <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred when labetalol injection was used during surgery (including when used in cases to control <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>).</p>
<p>A synergism between labetalol and halothane anesthesia has been shown (see <span class="Bold"><a href="#f11b1754-207b-4264-bcfa-c1502479b9ac">PRECAUTIONS - Drug Interactions</a></span>).</p>
<p><span class="Emphasis"><span class="Bold">Rapid Decreases of Blood Pressure </span></span></p>
<p>Caution must be observed when reducing severely elevated blood pressure. A number of adverse reactions, including <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span>, <span class="product-label-link" type="condition" conceptid="4131025" conceptname="Optic nerve infarction">optic nerve infarction</span>, angina, and ischemic changes in the electrocardiogram, have been reported with other agents when severely elevated blood pressure was reduced over time courses of several hours to as long as 1 or 2Â days. The desired blood pressure lowering should therefore be achieved over as long a period of time as is compatible with the patientâ€™s status.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f11b1754-207b-4264-bcfa-c1502479b9ac"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Emphasis"><span class="Bold">General</span></span></p>
<p><span class="Emphasis"><span class="Bold">Impaired Hepatic Function</span></span></p>
<p>Labetalol injection should be used with caution in patients with impaired hepatic function since metabolism of the drug may be diminished.</p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></span></p>
<p>Symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> (incidence 58%) is likely to occur if patients are tilted or allowed to assume the upright position within 3 hours of receiving labetalol injection. Therefore, the patient's ability to tolerate an upright position should be established before permitting any ambulation.</p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="436397" conceptname="Intraoperative floppy iris syndrome">Intraoperative Floppy Iris Syndrome</span> (IFIS) </span></span>has been observed during <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery in some patients treated with alpha-1 blockers (labetalol is an alpha/beta blocker). This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patientâ€™s ophthalmologist should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery. </p>
<p><span class="Emphasis"><span class="Bold">Following Coronary Artery Bypass Surgery</span></span></p>
<p>In one uncontrolled study, patients with low cardiac indices and elevated systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> following intravenous labetalol experienced significant declines in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> with little change in systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>. One of these patients developed <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> following labetalol treatment. Therefore, use of labetalol should be avoided in such patients.</p>
<p><span class="Emphasis"><span class="Bold">High-Dose Labetalol</span></span></p>
<p>Administration of up to 3 g/d as an infusion for up to 2 to 3 days has been anecdotally reported; several patients experienced <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> or Hepatic Dysfunction</span></span></p>
<p>(See <span class="Bold"><a href="#f4aaf679-d475-409b-a84a-225d94b0d447">WARNINGS</a></span>.)</p>
<p><span class="Emphasis"><span class="Bold">Information for Patients</span></span></p>
<p>The following information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. During and immediately following (for up to 3 hours) labetalol injection, the patient should remain supine. Subsequently, the patient should be advised on how to proceed gradually to become ambulatory, and should be observed at the time of first ambulation.</p>
<p>When the patient is started on labetalol hydrochloride tablets following adequate control of blood pressure with labetalol hydrochloride injection, appropriate directions for titration of dosage should be provided (see <span class="Bold"><a href="#f0b62ec3-df7b-4e2a-89a5-02d9048094ea">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>As with all drugs with beta-blocking activity, certain advice to patients being treated with labetalol is warranted: While no incident of the abrupt withdrawal phenomenon (exacerbation of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>) has been reported with labetalol, dosing with labetalol tablets should not be interrupted or discontinued without a physicianâ€™s advice. Patients being treated with labetalol tablets should consult a physician at any signs or symptoms of impending <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> or hepatic dysfunction (see <span class="Bold"><a href="#f4aaf679-d475-409b-a84a-225d94b0d447">WARNINGS</a></span>). Also, transient scalp <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> may occur, usually when treatment with labetalol tablets is initiated (see <span class="Bold"><a href="#e650c66a-e447-44af-8452-99c91c9f7b61">ADVERSE REACTIONS</a></span>).</p>
<p><span class="Emphasis"><span class="Bold">Laboratory Tests</span></span></p>
<p>Routine laboratory tests are ordinarily not required before or after intravenous labetalol. In patients with concomitant illnesses, such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, appropriate tests should be done to monitor these conditions.</p>
<p><span class="Emphasis"><span class="Bold">Drug Interactions</span></span></p>
<p>Since labetalol injection may be administered to patients already being treated with other medications, including other antihypertensive agents, careful monitoring of these patients is necessary to detect and treat promptly any undesired effect from concomitant administration.</p>
<p>In one survey, 2.3% of patients taking labetalol orally in combination with tricyclic antidepressants experienced <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> as compared to 0.7% reported to occur with labetalol alone. The contribution of each of the treatments to this adverse reaction is unknown but the possibility of a drug interaction cannot be excluded.</p>
<p>Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>; therefore, doses greater than the normal antiasthmatic dose of beta-agonist bronchodilator drugs may be required.</p>
<p>Cimetidine has been shown to increase the bioavailability of labetalol administered orally. Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol, special care should be used in establishing the dose required for blood pressure control in such patients.</p>
<p>Synergism has been shown between halothane anesthesia and intravenously administered labetalol. During controlled hypotensive anesthesia using labetalol in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> will be increased and because of the possibility of a large reduction in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and an increase in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol.</p>
<p>Labetalol blunts the <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> produced by nitroglycerin without preventing its hypotensive effect. If labetalol is used with nitroglycerin in patients with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, additional antihypertensive effects may occur.</p>
<p>Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.</p>
<p>When drug products that are alkaline, such as furosemide, have been administered in combination with labetalol, a white precipitate has been noted. Therefore, these drugs should not be administered in the same infusion line.</p>
<p><span class="Emphasis"><span class="Bold">Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span></span></span></p>
<p>While taking beta-blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p><span class="Emphasis"><span class="Bold">Drug/Laboratory Test Interactions</span></span></p>
<p>The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine, and vanillylmandelic acid (VMA) when measured by fluorimetric or photometric methods. In screening patients suspected of having a <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> and being treated with labetalol, a specific method, such as a high-performance liquid chromatographic assay with solid phase extraction (e.g., <span class="Emphasis"><span class="Italics">J Chromatogr.</span></span> 385:241, 1987) should be employed in determining levels of catecholamines.</p>
<p>Labetalol has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-LabÂ A<span class="Sup">Â®</span> (thin-layer chromatographic assay) and Emit-d.a.u.<span class="Sup">Â®</span> (radioenzymatic assay). When patients being treated with labetalol have a positive urine test for amphetamine using these techniques, confirmation should be made by using more specific methods, such as a gas chromatographic-<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometer technique.</p>
<p><span class="Emphasis"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></span></p>
<p>Long-term oral dosing studies with labetalol for 18 months in mice and for 2 years in rats showed no evidence of carcinogenesis. Studies with labetalol, using dominant lethal assays in rats and mice, and exposing microorganisms according to modified Ames tests, showed no evidence of mutagenesis.</p>
<p><span class="Emphasis"><span class="Bold">Pregnancy</span></span></p>
<p><span class="Emphasis"><span class="Bold">Teratogenic Effects</span></span></p>
<p><span class="Emphasis"><span class="Bold">Pregnancy Category C</span></span></p>
<p>Teratogenic studies have been performed with labetalol in rats and rabbits at oral doses up to approximately 6 and 4 times the maximum recommended human dose (MRHD), respectively. No reproducible evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> was observed. Increased fetal resorptions were seen in both species at doses approximating the MRHD. A teratology study performed with labetalol in rabbits at intravenous doses up to 1.7 times the MRHD revealed no evidence of drug-related harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Labetalol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Emphasis"><span class="Bold">Nonteratogenic Effects</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> have been reported in infants of mothers who were treated with labetalol for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy. Oral administration of labetalol to rats during late gestation through weaning at doses of 2 to 4 times the MRHD caused a decrease in neonatal survival.</p>
<p><span class="Emphasis"><span class="Bold">Labor and Delivery</span></span></p>
<p>Labetalol given to pregnant women with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> did not appear to affect the usual course of labor and delivery.</p>
<p><span class="Emphasis"><span class="Bold">Nursing Mothers</span></span></p>
<p>Small amounts of labetalol (approximately 0.004% of the maternal dose) are excreted in human milk. Caution should be exercised when labetalol injection is administered to a nursing woman.</p>
<p><span class="Emphasis"><span class="Bold">Pediatric Use</span></span></p>
<p>Safety and effectiveness in children have not been established.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="e650c66a-e447-44af-8452-99c91c9f7b61"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Labetalol injection is usually well tolerated. Most adverse effects have been mild and transient and in controlled trials involving 92 patients did not require labetalol withdrawal. Symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> (incidence 58%) is likely to occur if patients are tilted or allowed to assume the upright position within 3 hours of receiving labetalol injection. Moderate <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred in 1Â of 100Â patients while supine. Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> was noted in 4 of 100 patients, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> occurred in 1 of 100 patients.</p>
<p>The following also were reported with labetalol injection with the incidence per 100 patients as noted:</p>
<p><span class="Emphasis"><span class="Italics">Cardiovascular System:</span></span> <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular arrhythmia</span> in 1.</p>
<p><span class="Emphasis"><span class="Italics">Central and Peripheral Nervous Systems:</span></span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> in 9; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the scalp/skin 7; <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span> (<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>) and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, 1 each.</p>
<p><span class="Emphasis"><span class="Italics">Gastrointestinal System:</span></span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> in 13; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> 4; <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> and taste distortion, 1 each.</p>
<p><span class="Emphasis"><span class="Italics"><span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">Metabolic Disorders</span>:</span></span> Transient increases in blood urea nitrogen and serum creatinine levels occurred in 8 of 100 patients; these were associated with drops in blood pressure, generally in patients with prior <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p><span class="Emphasis"><span class="Italics">Psychiatric Disorders:</span></span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>/<span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span> in 3.</p>
<p><span class="Emphasis"><span class="Italics">Respiratory System:</span></span> <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span> in 1.</p>
<p><span class="Emphasis"><span class="Italics">Skin:</span></span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> in 1.</p>
<p>The incidence of adverse reactions depends upon the dose of labetalol. The largest experience is with oral labetalol. Certain of the side effects increased with increasing oral dose as shown in the table below which depicts the entire U.S. therapeutic trials data base for adverse reactions that are clearly or possibly dose related.</p>
<table width="100%">
<col width="31%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="7%">
<col width="9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Emphasis"><span class="Bold">Labetalol Daily Dose (mg)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">200</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">300</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">400</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">600</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">800</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">900</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">1200</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">1600</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">2400</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Number of Patients</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">522</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">181</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">606</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">608</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">503</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">117</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">411</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">242</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">175</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">13</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">11</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">19</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">5</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Stuffiness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">5</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">Ejaculation Failure</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p>In addition, a number of other less common adverse events have been reported:</p>
<p><span class="Emphasis"><span class="Italics">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, and rarely, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.</p>
<p><span class="Emphasis"><span class="Italics">Liver and Biliary System:</span></span> <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">Hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, elevated liver function tests.</p>
<p><span class="Emphasis"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span></span> Rare reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>) and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4317263" conceptname="Ocular-mucous membrane syndrome">oculomucocutaneous syndrome</span> associated with the beta-blocker practolol has not been reported with labetalol during investigational use and extensive foreign marketing experience.</p>
<p><span class="Emphasis"><span class="Bold">Clinical Laboratory Tests</span></span></p>
<p>Among patients dosed with labetalol tablets, there have been reversible increases of serum transaminases in 4% of patients tested, and more rarely, reversible increases in blood urea.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="f41359cc-7e59-467e-8198-6d2ed4596e85"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage with labetalol injection causes excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> that is posture sensitive, and sometimes, excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Patients should be placed supine and their legs raised if necessary to improve the blood supply to the brain. If overdosage with labetalol follows oral ingestion, gastric lavage or pharmacologically induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (using syrup of ipecac) may be useful for removal of the drug shortly after ingestion. The following additional measures should be employed if necessary: <span class="Emphasis"><span class="Italics">Excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span></span></span>-administer atropine or epinephrine. <span class="Emphasis"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span></span></span>-administer a digitalis glycoside and a diuretic. Dopamine or dobutamine may also be useful. <span class="Emphasis"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>-</span></span>administer vasopressors, e.g., norepinephrine. There is pharmacological evidence that norepinephrine may be the drug of choice. <span class="Emphasis"><span class="Italics"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>-</span></span>administer epinephrine and/or an aerosolized beta<span class="Sub">2</span>-agonist. <span class="Emphasis"><span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>-</span></span>administer diazepam.</p>
<p>In severe beta-blocker <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> resulting in <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, glucagon has been shown to be effective when administered in large doses (5 to 10 mg rapidly over 30 seconds, followed by continuous infusion of 5 mg/hr that can be reduced as the patient improves).</p>
<p>Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol from the general circulation (&lt;1%).</p>
<p>The oral LD<span class="Sub">50</span> value of labetalol in the mouse is approximately 600 mg/kg and in the rat is greater than 2 g/kg. The intravenous LD<span class="Sub">50</span> in these species is 50 to 60 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f0b62ec3-df7b-4e2a-89a5-02d9048094ea"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Labetalol hydrochloride injection is intended for intravenous use in hospitalized patients. DOSAGE MUST BE INDIVIDUALIZED depending upon the severity of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and the response of the patient during dosing.</p>
<p><span class="Emphasis"><span class="Bold">Patients should always be kept in a supine position during the period of intravenous drug administration. A substantial <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> on standing should be expected in these patients. The patientâ€™s ability to tolerate an upright position should be established before permitting any ambulation, such as using toilet facilities.</span></span></p>
<p>Either of two methods of administration of labetalol hydrochloride injection may be used: a)Â repeated intravenous injections, b) slow continuous infusion.</p>
<p><span class="Emphasis"><span class="Bold">Repeated Intravenous Injection</span></span></p>
<p>Initially, labetalol hydrochloride injection should be given in a dose of 20 mg labetalol HCl (which corresponds to 0.25 mg/kg for an 80 kg patient) by slow intravenous injection over a 2-minute period.</p>
<p>Immediately before the injection and at 5 and 10 minutes after injection, supine blood pressure should be measured to evaluate response. Additional injections of 40 mg or 80 mg can be given at 10 minute intervals until a desired supine blood pressure is achieved or a total of 300 mg labetalol HCl has been injected. The maximum effect usually occurs within 5 minutes of each injection.</p>
<p><span class="Emphasis"><span class="Bold">Slow Continuous Infusion</span></span></p>
<p>Labetalol hydrochloride injection is prepared for continuous intravenous infusion by diluting the contents with commonly used intravenous fluids (see below). Examples of methods of preparing the infusion solution are:</p>
<p>The contents of either two 20 mL vials (40 mL), or one 40 mL vial, are added to 160 mL of a commonly used intravenous fluid such that the resultant 200 mL of solution contains 200 mg of labetalol hydrochloride, 1 mg/mL. The diluted solution should be administered at a rate of 2Â mL/min to deliver 2 mg/min.</p>
<p>Alternatively, the contents of either two 20 mL vials (40 mL), or one 40 mL vial, of labetalol hydrochloride injection are added to 250 mL of a commonly used intravenous fluid. The resultant solution will contain 200 mg of labetalol hydrochloride, approximately 2 mg/3 mL. The diluted solution should be administered at a rate of 3 mL/min to deliver approximately 2 mg/min.</p>
<p>The rate of infusion of the diluted solution may be adjusted according to the blood pressure response, at the discretion of the physician. To facilitate a desired rate of infusion, the diluted solution can be infused using a controlled administration mechanism, e.g., graduated burette or mechanically driven infusion pump.</p>
<p>Since the half-life of labetalol is 5 to 8 hours, steady-state blood levels (in the face of a constant rate of infusion) would not be reached during the usual infusion time period. The infusion should be continued until a satisfactory response is obtained and should then be stopped and oral labetalol hydrochloride started. The effective intravenous dose is usually in the range of 50 to 200 mg. A total dose of up to 300 mg may be required in some patients.</p>
<p><span class="Emphasis"><span class="Bold">Blood Pressure Monitoring</span></span></p>
<p>The blood pressure should be monitored during and after completion of the infusion or intravenous injections. Rapid or excessive <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> in either systolic or diastolic blood pressure during intravenous treatment should be avoided. In patients with excessive <span class="product-label-link" type="condition" conceptid="4209293" conceptname="Systolic hypertension">systolic hypertension</span>, the decrease in systolic pressure should be used as indicator of effectiveness in addition to the response of the diastolic pressure.</p>
<p><span class="Emphasis"><span class="Bold">Initiation of Dosing with Labetalol Hydrochloride Tablets</span></span></p>
<p>Subsequent oral dosing with labetalol hydrochloride tablets should begin when it has been established that the supine diastolic blood pressure has begun to rise. The recommended initial dose is 200 mg, followed in 6 to 12Â hours by an additional dose of 200 or 400 mg, depending on the blood pressure response. Thereafter, <span class="Emphasis"><span class="Italics">inpatient titration with labetalol hydrochloride tablets</span></span> may proceed as follows:</p>
<table width="100%">
<caption><span>Inpatient Titration Instructions</span></caption>
<col width="50%">
<col width="50%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>If needed, the total daily dose may be given in three divided doses.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Emphasis"><span class="Bold">Regimen</span></span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Daily Dose</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">200 mg b.i.d.</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">400 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">400 mg b.i.d.</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">800 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">800 mg b.i.d.</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1600 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1200 mg b.i.d.</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2400 mg</p></td>
</tr>
</tbody>
</table>
<p>While in the hospital, the dosage of labetalol hydrochloride tablets may be increased at 1 day intervals to achieve the desired blood pressure reduction.</p>
<p>For subsequent outpatient titration or maintenance dosing see Labetalol Hydrochloride Tablets Product Information <span class="Bold"><a href="#f0b62ec3-df7b-4e2a-89a5-02d9048094ea">DOSAGE AND ADMINISTRATION </a></span>for additional recommendations.</p>
<p><span class="Emphasis"><span class="Bold">Compatibility with commonly used intravenous fluids</span></span></p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p>Labetalol hydrochloride injection was tested for compatibility with commonly used intravenous fluids at final concentrations of 1.25 mg to 3.75 mg labetalol hydrochloride per mL of the mixture. Labetalol hydrochloride injection was found to be compatible with and stable (for 24 hours refrigerated or at room temperature) in mixtures with the following solutions:</p>
<p>Ringers Injection, USP</p>
<p>Lactated Ringers Injection, USP</p>
<p>5% Dextrose and Ringers Injection</p>
<p>5% Lactated Ringers and 5% Dextrose Injection</p>
<p>5% Dextrose Injection, USP</p>
<p>0.9% Sodium Chloride Injection, USP</p>
<p>5% Dextrose and 0.2% Sodium Chloride Injection, USP</p>
<p>2.5% Dextrose and 0.45% Sodium Chloride Injection, USP</p>
<p>5% Dextrose and 0.9% Sodium Chloride Injection, USP</p>
<p>5% Dextrose and 0.33% Sodium Chloride Injection, USP</p>
<p>Labetalol hydrochloride injection was NOT compatible with 5% Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Injection, USP. Care should be taken when administering alkaline drugs, including furosemide, in combination with labetalol. Compatibility should be assured prior to administering these drugs together.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="f0942e88-0380-47e3-964e-465ea3595d09"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Labetalol hydrochloride injection, USP 5 mg/mL, is supplied in:</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Unit of Sale</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Concentration</span></p></td>
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Each</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First"><span class="Bold">NDC 0409-2267-25</span></p>
<p>Carton of 1</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">100 mg/20 mL</p>
<p>(5 mg/mL)</p>
</td>
<td class="Botrule Lrule Toprule" valign="top">
<p class="First">NDC 0409-2267-25</p>
<p>20 mL Multidose Vial</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">NDC 0409-2267-26</span></p>
<p>Carton of 1</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">200 mg/40 mL</p>
<p>(5 mg/mL)</p>
</td>
<td class="Botrule Lrule Toprule" valign="top">
<p class="First">NDC 0409-2267-26</p>
<p>40 mL Multidose Vial</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Store at 20 to 25Â° C (68 to 77Â° F). [See USP Controlled Room Temperature.] Protect from freezing and light.</span></p>
<p>Revised: 5/2015</p>
<p>Â Â </p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â EN-3924</p>
<p>Â </p>
<p>Manufactured by Hospira, Inc., Lake Forest, IL 60045 USA<br><a name="id1135913727"></a><img alt="Novaplus logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f6e529bf-fe4d-4091-a3c2-774245b5f0a1&amp;name=novaplus-logo-02.jpg"><br>N+ and NOVAPLUS are registered trademarks of Novation, LLC.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bf941d8d-8c1c-4b4b-a448-27e04709a1dd"></a><a name="section-12"></a><p></p>
<h1>CA-3966</h1>
<div class="Figure">
<a name="id-257528396"></a><img alt="Carton NDC 0409-2267-25" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f6e529bf-fe4d-4091-a3c2-774245b5f0a1&amp;name=ca-3966.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LABETALOL HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">labetalol hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-2267</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LABETALOL HYDROCHLORIDE</strong> (LABETALOL) </td>
<td class="formItem">LABETALOL HYDROCHLORIDE</td>
<td class="formItem">5Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS DEXTROSE</strong></td>
<td class="formItem">45Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">0.1Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">0.8Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">0.1Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-2267-25</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0409-2267-26</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">40 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075240</td>
<td class="formItem">07/22/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Hospira, Inc.
							(141588017)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>836b9a5f-70f0-485b-93a2-0e7dc1b603a1</div>
<div>Set id: f6e529bf-fe4d-4091-a3c2-774245b5f0a1</div>
<div>Version: 2</div>
<div>Effective Time: 20150911</div>
</div>
</div>Â <div class="DistributorName">Hospira, Inc.</div></p>
</body></html>
